Research programme: factor Xa inhibitors - Schering-Plough

Drug Profile

Research programme: factor Xa inhibitors - Schering-Plough

Alternative Names: Factor Xa inhibitors research programme - Schering-Plough; Oral anticoagulants research programme - Schering-Plough

Latest Information Update: 26 Sep 2002

Price : $50

At a glance

  • Originator Dendreon San Diego LLC
  • Developer Schering-Plough
  • Class
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Deep vein thrombosis; Embolism; Myocardial infarction; Unstable angina pectoris

Most Recent Events

  • 26 Sep 2002 Corvas International has terminated its involvement in the research collaboration
  • 03 Feb 1999 Preclinical development for Deep vein thrombosis in USA (PO)
  • 03 Feb 1999 Preclinical development for Embolism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top